STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD(GPCR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

GPCR STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD

Pre-Mkt 10-30 06:07:51 EDT

21.94

+0.46

+2.14%

盘前21.94

+0.000.00%

04:00 EDT

High22.16	Low21.39	Vol929.52K
Open21.51	D1 Closing21.48	Amplitude3.61%
Mkt Cap1.56B	Tradable Cap1.22B	Total Shares71.31M
T/O20.29M	T/O Rate1.68%	Tradable Shares55.46M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"GPCR","market":"US","secType":"STK","nameCN":"STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD","latestPrice":21.94,"timestamp":1793304000000,"preClose":21.48,"halted":0,"volume":929515,"hourTrading":{"tag":"盘前","latestPrice":21.94,"preClose":21.94,"latestTime":"04:00 EDT","volume":3,"amount":65.82000000000001,"timestamp":1793347227845,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.021415270018622014,"floatShares":55463000,"shares":71309857,"eps":-3.1128,"marketStatus":"Pre-Mkt","change":0.46,"latestTime":"10-30 06:07:51 EDT","open":21.51,"high":22.1644,"low":21.39,"amount":20293626.012835,"amplitude":0.036052,"askPrice":26.05,"askSize":100,"bidPrice":19.32,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-3.1128,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1793367000000},"marketStatusCode":1,"adr":0,"adrRate":3,"listingDate":1675400400000,"exchange":"NASDAQ","adjPreClose":21.94,"preHourTrading":{"tag":"盘前","latestPrice":21.94,"preClose":21.94,"latestTime":"04:00 EDT","volume":3,"amount":65.82000000000001,"timestamp":1793347227845,"change":0,"changeRate":0,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":21.9655,"preClose":21.94,"latestTime":"19:53 EDT","volume":14302,"amount":313559.185,"timestamp":1793318039156,"change":0.0255,"changeRate":0.001162,"amplitude":0.014412},"volumeRatio":1.1890778531464832,"impliedVol":1.1605,"impliedVolPercentile":0.88},"requestUrl":"/m/hq/s/GPCR","defaultTab":"news","newsList":[{"id":"2676812636","title":"Structure Therapeutics Announces Aleniglipron Trial Presentations at ObesityWeek 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2676812636","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2676812636?lang=en_us&edition=fundamental","pubTime":"2026-10-20 04:22","pubTimestamp":1792441369,"startTime":"0","endTime":"0","summary":"Structure Therapeutics Announces Aleniglipron Trial Presentations at ObesityWeek 2026Structure Therapeutics will present aleniglipron obesity trial research at ObesityWeek on Nov. 15, 2026, in Nationa","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261019:nNDL3MpMlR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","SG9999014021.USD","IE00BKPKM429.USD","BK4588","GPCR","LU2210149790.SGD","NDAQ","IE00BN0W2T93.GBP","BK4112","BCDF","IE00BGHQF748.EUR","LU0314104364.USD","IE00BN0W2V16.EUR","BK4007","IE00BN0W2W23.USD","LU2095319765.USD","IE00B64PRP62.GBP","SG9999014013.SGD","IE00BQXX3F31.USD","IE00BQXX3C00.GBP","BK4585","LU2210150020.SGD","SG9999014039.USD","SG9999014005.SGD","IE00BQXX3D17.EUR","BK4599"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676636084","title":"Structure Therapeutics Announces Multiple Upcoming Presentations at ObesityWeek® 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2676636084","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2676636084?lang=en_us&edition=fundamental","pubTime":"2026-10-20 04:13","pubTimestamp":1792440780,"startTime":"0","endTime":"0","summary":"SAN FRANCISCO, Oct.  19, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for me","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/19/3383889/0/en/structure-therapeutics-announces-multiple-upcoming-presentations-at-obesityweek-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4139","LENZ","BK4007","BK4599","GPCR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676500927","title":"China's Hansoh Pharma Strikes Drug Deal with Roche Worth over $15 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=2676500927","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2676500927?lang=en_us&edition=fundamental","pubTime":"2026-10-19 18:58","pubTimestamp":1792407499,"startTime":"0","endTime":"0","summary":"UPDATE 2-China's Hansoh Pharma strikes drug deal with Roche worth over $15 billionOct 19 (Reuters)-China's Hansoh Pharmaceutical3692.HKsaid on Monday it has entered into a partnership and licensing de","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261019:nL4N4650QG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1969619763.USD","03692","LU0405327148.USD","LU1236620750.USD","LU2360032135.SGD","BK0028","LU1064130708.USD","LU0321505868.SGD","LU1670710661.SGD","BK0188","LU1328615791.USD","LU0405327494.USD","LU2242646821.SGD","LU0868494617.USD","IE00BFXG1179.USD","LU1868837300.USD","BK1589","LU1997245094.SGD","BK0196","IHE","BK0060","LU1261432733.SGD","LU1718418525.SGD","BMY","LU0225771236.USD","LU2125154935.USD","LU0061475181.USD","FTXH","LU0432979614.USD","LU1064131003.USD","GPCR","LU2097828474.EUR","LU0985481810.HKD","LU2495084118.USD","LU2328871848.SGD","BK4532","LU2133065610.SGD","IE0009355771.USD","BK1191","LU2097828557.USD","IE0002141913.USD","IE00BFTCPJ56.SGD","BK4599","LU2289578879.USD","LU1323610961.USD","LU1868836914.USD","BK4581","LU0456855351.SGD","600276","LU1781817850.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675321709","title":"Structure Therapeutics Currently Down 14 Consecutive Days, on Pace for Record Losing Streak","url":"https://stock-news.laohu8.com/highlight/detail?id=2675321709","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675321709?lang=en_us&edition=fundamental","pubTime":"2026-10-15 02:49","pubTimestamp":1792003740,"startTime":"0","endTime":"0","summary":"Structure Therapeutics, Inc. Sponsored ADR  is currently at $22.28, down $0.03 or 0.13%--Would be lowest close since Sept. 17, 2025, when it closed at $21.65--On pace for largest percent decrease since Oct. 13, 2026, when it fell 6.69%--Currently down 15 of the past 16 days--Currently down 14 consecutive days; down 38.15% over this period--Longest losing streak on record --Worst 14 day stretch since the 14 days ending Dec. 28, 2023, when it fell 38.27%--Down 28.75% month-to-date--Down 67.97% year-to-date; on pace for worst year on record --Down 76.24% from its all-time closing high of $93.79 on Jan. 21, 2026--Down 23.78% from 52 weeks ago , when it closed at $29.23--Down 76.24% from its 52-week closing high of $93.79 on Jan. 21, 2026--Would be a new 52-week closing low--Traded as low as $21.55; lowest intraday level since Sept. 17, 2025, when it hit $20.92--Down 3.41% at today's intraday lowAll data as of 2:47:20 PM ETSource: Dow Jones Market Data, FactSet","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4007","GPCR","LENZ","BK4139","BK4599"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674100941","title":"Structure Therapeutics on Track for Lowest Close Since September 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2674100941","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674100941?lang=en_us&edition=fundamental","pubTime":"2026-10-09 00:19","pubTimestamp":1791476340,"startTime":"0","endTime":"0","summary":"Structure Therapeutics, Inc. Sponsored ADR  is currently at $25.34, down $1.34 or 5.02%--Would be lowest close since Sept. 29, 2025, when it closed at $25.30--On pace for largest percent decrease since Oct. 1, 2026, when it fell 7.32%--Currently down 11 of the past 12 days--Currently down 10 consecutive days; down 29.65% over this period--Longest losing streak on record --Worst 10 day stretch since the 10 days ending April 8, 2025, when it fell 30.43%--Down 18.96% month-to-date--Down 63.57% year-to-date; on pace for worst year on record --Down 72.98% from its all-time closing high of $93.79 on Jan. 21, 2026--Down 17.05% from 52 weeks ago , when it closed at $30.55--Down 72.98% from its 52-week closing high of $93.79 on Jan. 21, 2026--Would be a new 52-week closing low--Traded as low as $25.20; lowest intraday level since Sept. 30, 2025, when it hit $24.99--Down 5.53% at today's intraday lowAll data as of 12:15:42 PM ETSource: Dow Jones Market Data, FactSet","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LENZ","BK4599","BK4539","BK4007","GPCR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198490653","title":"23% Weight Loss, 27% Dropouts: How Strong Is Lilly's Phase 2 Combo, Really?","url":"https://stock-news.laohu8.com/highlight/detail?id=1198490653","media":"Options & Short Sell","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1198490653?lang=en_us&edition=fundamental","pubTime":"2026-10-01 07:58","pubTimestamp":1790812717,"startTime":"0","endTime":"0","summary":"","market":"other","thumbnail":"https://static.tigerbbs.com/8818ec487bcc6265f08776aa6beddf07","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/8818ec487bcc6265f08776aa6beddf07"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"23% Weight Loss, 27% Dropouts: How Strong Is Lilly's Phase 2 Combo, Really?","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVOX","NVOC","PFE","NVO","VKTX","NVOH","ELIS","LLY","GPCR","LLYX","LLII","AMGN","ELIL","RHHBY"],"isVideo":true,"video":{"duration":153,"video_url":"https://news-video-sg.skytigris.cn/videos/remotion/2943/render_2943_1790812083911.mp4","video_thumbnail":"https://community-static.tradeup.com/news/b064c13057afaef2771b273441eaa207","audio_url":"https://news-video-sg.skytigris.cn/videos/remotion/2943/tts/voiceover_61d6040c80e6655f.mp3","isAI":true},"gpt_icon":0},{"id":"2669203171","title":"Structure Therapeutics CMO Blas Coll Crespo Disposes of USD 124,008 Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2669203171","media":"Reuters","labels":["executive","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669203171?lang=en_us&edition=fundamental","pubTime":"2026-09-23 06:00","pubTimestamp":1790114427,"startTime":"0","endTime":"0","summary":"Structure Therapeutics CMO Blas Coll Crespo disposes of USD 124,008 common sharesStructure Therapeutics Chief Medical Officer Blas Coll Crespo cut his ordinary share stake to 258,228 shares.Disposed o","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nNDL1GxjGX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Structure Therapeutics CMO Blas Coll Crespo Disposes of USD 124,008 Common Shares","news_tag":"executive,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4599","GPCR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184942432","title":"Lilly: Foundayo Has Captured Over 30% Of New Patient Share In The U.S. Oral Weight-Loss Drug Market","url":"https://stock-news.laohu8.com/highlight/detail?id=1184942432","media":"Bellwether Stocks Movement","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1184942432?lang=en_us&edition=fundamental","pubTime":"2026-09-15 19:30","pubTimestamp":1789471823,"startTime":"0","endTime":"0","summary":"","market":"sg","thumbnail":"https://static.tigerbbs.com/22762b6dea5c8c5c89879a7f215d2c61","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/22762b6dea5c8c5c89879a7f215d2c61"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Lilly: Foundayo has captured over 30% of new patient share in the U.S. oral weight-loss drug market.","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LLY","ELIL","THNR","LLYX","RHHBY","VKTX","NVOH","ELIS","AMGN","LLII","PFE","NVO","NVOC","NVOX","GPCR"],"isVideo":true,"video":{"duration":91,"video_url":"https://news-video-sg.skytigris.cn/videos/remotion/1658/render_1658_1789471552256.mp4","video_thumbnail":"https://news-video-sg.skytigris.cn/videos/covers/1658.webp","audio_url":"https://news-video-sg.skytigris.cn/videos/remotion/1658/tts/voiceover_4381bf9c1e0a769a.mp3","isAI":true},"gpt_icon":0},{"id":"1156243998","title":"AstraZeneca's Breast Cancer Drug Etcamah Hits A Phase 3 Setback, Clouding Billions In Potential Sales","url":"https://stock-news.laohu8.com/highlight/detail?id=1156243998","media":"Options & Short Sell","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1156243998?lang=en_us&edition=fundamental","pubTime":"2026-09-14 17:14","pubTimestamp":1789377246,"startTime":"0","endTime":"0","summary":"","market":"fut","thumbnail":"https://news-video-sg.skytigris.cn/videos/covers/1496.webp","type":0,"news_type":0,"thumbnails":["https://news-video-sg.skytigris.cn/videos/covers/1496.webp"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"AstraZeneca's Breast Cancer Drug Etcamah Hits a Phase 3 Setback, Clouding Billions in Potential Sales","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GPCR","NVOC","AMGN","NVOX","ELIL","IBBQ","LLY","ELIS","PFE","NVO","VKTX","LLII","NVOH","AZN","BMED","LLYX","RHHBY","MDTX","IBBJ","PSYK"],"isVideo":true,"video":{"duration":182,"video_url":"https://news-video-sg.skytigris.cn/videos/remotion/1496/render_1496_1789375598294.mp4","video_thumbnail":"https://news-video-sg.skytigris.cn/videos/covers/1496.webp","audio_url":"https://news-video-sg.skytigris.cn/videos/remotion/1496/tts/voiceover_628d329bc79f3f40.mp3","isAI":true},"gpt_icon":0},{"id":"1148604610","title":"GE HealthCare Plans $1 Billion Sofie Deal To Tap Fast-Growing Radiopharmaceuticals Market","url":"https://stock-news.laohu8.com/highlight/detail?id=1148604610","media":"Options & Short Sell","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1148604610?lang=en_us&edition=fundamental","pubTime":"2026-09-14 11:57","pubTimestamp":1789358223,"startTime":"0","endTime":"0","summary":"","market":"uk","thumbnail":"https://static.tigerbbs.com/3d1e60086e7507a7d585b7a37ec5f921","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/3d1e60086e7507a7d585b7a37ec5f921"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"GE HealthCare Plans $1 Billion Sofie Deal to Tap Fast-Growing Radiopharmaceuticals Market","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0124676726.USD","NVOC","VKTX","BK4082","NVO","RHHBY","PFE","ELIS","LLYX","GPCR","LLY","BK4585","NVOX","LLII","ELIL","LGHT","GEHC","BK4588","NVOH","LU0689626769.HKD","AMGN"],"isVideo":true,"video":{"duration":84,"video_url":"https://news-video-sg.skytigris.cn/videos/remotion/1451/render_1451_1789353130349.mp4","video_thumbnail":"https://news-video-sg.skytigris.cn/videos/covers/1451.webp","audio_url":"https://news-video-sg.skytigris.cn/videos/remotion/1451/tts/voiceover_9298458f7ca9ec5b.mp3","isAI":true},"gpt_icon":0},{"id":"2666377632","title":"Structure weakness ‘disconnected’ from underlying data, says Jefferies","url":"https://stock-news.laohu8.com/highlight/detail?id=2666377632","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666377632?lang=en_us&edition=fundamental","pubTime":"2026-09-09 04:00","pubTimestamp":1788897615,"startTime":"0","endTime":"0","summary":"After Structure Therapeutics (GPCR) reported clinical trial results from its two lead product candidates, ACCG-2671 and aleniglipron, Jefferies see...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/structure-weakness-disconnected-from-underlying-data-says-jefferies-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/structure-weakness-disconnected-from-underlying-data-says-jefferies-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AZNH","BIB","IBBQ","GNMX","IDNA","PSIL","HRTS","MNTL","GDOC","TBXU","PINK","PTH","SBIO","MEDX","HYLG","PBE","BBH","LLYX","RSPH","BME","IBRN","XPH","BBP","MRNY","APXH","GNOM","MEDI","CANC","CNCR","GSKH","FTXH","SYNB","FXH","FHLC","NVIB","FBT","JDOC","IBBJ","PSCH","LFSC","SURI","CURE","GPCR","IBB","IEIH","JHMH","PBPH","WDNA","PJP","MDTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666372171","title":"Structure Falls as Investors Await More Obesity Trial Data, Says Jefferies","url":"https://stock-news.laohu8.com/highlight/detail?id=2666372171","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666372171?lang=en_us&edition=fundamental","pubTime":"2026-09-09 03:47","pubTimestamp":1788896852,"startTime":"0","endTime":"0","summary":"BUZZ-Structure falls as investors await more obesity trial data, says Jefferies** Shares of Structure TherapeuticsGPCR.Ofall 13.4% to $40.73** Brokerage Jefferies says weakness in the stock following ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nL4N4501KC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GPCR","BK4599","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666275371","title":"Analysts Are Bullish on These Healthcare Stocks: enGene Holdings (ENGN), Structure Therapeutics, Inc. Sponsored ADR (GPCR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2666275371","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666275371?lang=en_us&edition=fundamental","pubTime":"2026-09-09 00:40","pubTimestamp":1788885608,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on enGene Holdings (ENGN) and Structure Therapeutics, I...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-engene-holdings-engn-structure-therapeutics-inc-sponsored-adr-gpcr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-engene-holdings-engn-structure-therapeutics-inc-sponsored-adr-gpcr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","CVY","LABU","GPCR","ENGN","SAPH","DIVL","AADR","LU0128526141.USD","XBI","DINT","LU0029874061.USD","APIE","BK4585","BK4139","HCSG","BK4137","BK4007","BK4581","XLV","BK4599","ARMH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666714353","title":"Structure obesity portfolio updates ‘encouraging,’ says Clear Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2666714353","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666714353?lang=en_us&edition=fundamental","pubTime":"2026-09-09 00:20","pubTimestamp":1788884454,"startTime":"0","endTime":"0","summary":"Clear Street says Structure Therapeutics (GPCR) announced “encouraging updates “across its obesity portfolio. ACCG-2671 is beginning to unlock valu...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/structure-obesity-portfolio-updates-encouraging-says-clear-street-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/structure-obesity-portfolio-updates-encouraging-says-clear-street-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4599","GPCR","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665637847","title":"Structure Therapeutics reports ACCG-2671, aleniglipron trial results","url":"https://stock-news.laohu8.com/highlight/detail?id=2665637847","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665637847?lang=en_us&edition=fundamental","pubTime":"2026-09-08 20:36","pubTimestamp":1788871007,"startTime":"0","endTime":"0","summary":"Structure Therapeutics (GPCR) reported clinical trial results from its two lead product candidates: ACCG-2671, an oral, non-peptide, small molecule...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/structure-therapeutics-reports-accg-2671-aleniglipron-trial-results-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/structure-therapeutics-reports-accg-2671-aleniglipron-trial-results-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AZNH","BBH","BBP","HYLG","LLYX","GNMX","XPH","JDOC","BME","PINK","FXH","TBXU","CURE","MNTL","LENZ","GPCR","IBB","SURI","LFSC","MDTX","CNCR","IBBJ","SBIO","HRTS","FHLC","MEDX","FBT","WDNA","MEDI","IBBQ","GSKH","CANC","PBE","APXH","RSPH","GNOM","SYNB","FTXH","PJP","GDOC","BIB","IBRN","PTH","PSIL","PSCH","JHMH","MRNY","IDNA","PBPH","NVIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665378828","title":"Structure Therapeutics Releases Amylin and GLP-1 Program Presentation","url":"https://stock-news.laohu8.com/highlight/detail?id=2665378828","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665378828?lang=en_us&edition=fundamental","pubTime":"2026-09-08 20:25","pubTimestamp":1788870333,"startTime":"0","endTime":"0","summary":"Structure Therapeutics releases amylin and GLP-1 program presentationStructure Therapeutics released a presentation outlining updates on its oral obesity pipeline, highlighting ACCG-2671 as an oral am","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nNDL6ZLbk7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4599","BK4007","GPCR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665320931","title":"Structure Therapeutics Reports Phase 1/2a Data Showing 3.3% Weight Loss for Oral Amylin Agonist ACCG-2671","url":"https://stock-news.laohu8.com/highlight/detail?id=2665320931","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665320931?lang=en_us&edition=fundamental","pubTime":"2026-09-08 20:06","pubTimestamp":1788869185,"startTime":"0","endTime":"0","summary":"Structure Therapeutics reports Phase 1/2a data showing 3.3% weight loss for oral amylin agonist ACCG-2671Structure Therapeutics reported positive early-stage results for ACCG-2671, an oral amylin-base","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nNDLccRw3t:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BQXX3D17.EUR","SG9999014039.USD","IE00BN0W2V16.EUR","IE00B3QW5Z07.USD","IE00BN0W2T93.GBP","SG9999014005.SGD","SG9999014013.SGD","SG9999014021.USD","BK4599","BK4588","IE00BQXX3C00.GBP","LU2210149790.SGD","GPCR","IE00BQXX3F31.USD","LU2210150020.SGD","IE00B64PRP62.GBP","BK4585","BCDF","BK4007","IE00BKPKM429.USD","LU2095319765.USD","BK4112","LU0314104364.USD","NDAQ","IE00BGHQF748.EUR","IE00BN0W2W23.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665512320","title":"Structure Therapeutics - Aleniglipron Demonstrates up to 16.2% Body Weight Reduction at 72 Weeks in Access Ole Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2665512320","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665512320?lang=en_us&edition=fundamental","pubTime":"2026-09-08 20:00","pubTimestamp":1788868806,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nTUA4H9CBL:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4599","GPCR","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665332058","title":"Structure Therapeutics - Accg-2671 Demonstrates About 6-Day Half-Life, no Serious Adverse Events, 3.3% Body Weight Loss in Phase 1/2a Sad Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2665332058","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665332058?lang=en_us&edition=fundamental","pubTime":"2026-09-08 20:00","pubTimestamp":1788868806,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nTUA4H9CBL:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","GPCR","BK4599"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665320587","title":"Structure Therapeutics - Additional Clinical Data for Aleniglipron Expected in Q4 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2665320587","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665320587?lang=en_us&edition=fundamental","pubTime":"2026-09-08 20:00","pubTimestamp":1788868806,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nTUA4H9CBL:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GPCR","BK4599","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.structuretx.com","stockEarnings":[{"period":"1week","weight":0.0005},{"period":"1month","weight":-0.3288},{"period":"3month","weight":-0.5433},{"period":"6month","weight":-0.4802},{"period":"1year","weight":-0.258},{"period":"ytd","weight":-0.6845}],"compareEarnings":[{"period":"1week","weight":0.0071},{"period":"1month","weight":0.0068},{"period":"3month","weight":0.0299},{"period":"6month","weight":0.0676},{"period":"1year","weight":0.1192},{"period":"ytd","weight":0.1282}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist, targeting apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension; and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF. The company was formerly known as ShouTi Inc. The company was founded in 2016 and is headquartered in South San Francisco, California.","yearOnYearQuotes":[{"month":1,"riseRate":1,"avgChangeRate":0.149001},{"month":2,"riseRate":0,"avgChangeRate":-0.188474},{"month":3,"riseRate":0.25,"avgChangeRate":-0.12966},{"month":4,"riseRate":0.5,"avgChangeRate":0.102223},{"month":5,"riseRate":0.25,"avgChangeRate":-0.029871},{"month":6,"riseRate":0.75,"avgChangeRate":0.191173},{"month":7,"riseRate":0,"avgChangeRate":-0.102138},{"month":8,"riseRate":0.5,"avgChangeRate":-0.043717},{"month":9,"riseRate":0.75,"avgChangeRate":0.267883},{"month":10,"riseRate":0.5,"avgChangeRate":0.075706},{"month":11,"riseRate":0.333333,"avgChangeRate":-0.123384},{"month":12,"riseRate":0.333333,"avgChangeRate":0.164068}],"exchange":"NASDAQ","name":"STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD","nameEN":"STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD","securityTypeName":"DR","adrRate":"1:3"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.52.1","shortVersion":"4.52.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD(GPCR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD(GPCR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD,GPCR,STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD股票,STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD股票老虎,STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD股票老虎国际,STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD行情,STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD股票行情,STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD股价,STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD股市,STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD股票价格,STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD股票交易,STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD股票购买,STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD(GPCR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD(GPCR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}